Article ; Online: Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
2020 Volume 11, Issue 10, Page(s) 707–722
Abstract: ... with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die ... morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ... The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome ...
| Abstract | The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS. |
|---|---|
| MeSH term(s) | Adoptive Transfer ; Alveolar Epithelial Cells/pathology ; Animals ; Apoptosis ; Betacoronavirus ; Body Fluids/metabolism ; CD4-Positive T-Lymphocytes/immunology ; COVID-19 ; Clinical Trials as Topic ; Coinfection/prevention & control ; Coinfection/therapy ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Disease Models, Animal ; Endothelial Cells/pathology ; Extracorporeal Membrane Oxygenation ; Genetic Therapy/methods ; Genetic Vectors/administration & dosage ; Genetic Vectors/therapeutic use ; Humans ; Immunity, Innate ; Inflammation Mediators/metabolism ; Lung/pathology ; Lung/physiopathology ; Mesenchymal Stem Cell Transplantation/methods ; Mesenchymal Stem Cells/physiology ; Multiple Organ Failure/etiology ; Multiple Organ Failure/prevention & control ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Respiratory Distress Syndrome/immunology ; Respiratory Distress Syndrome/pathology ; Respiratory Distress Syndrome/therapy ; SARS-CoV-2 ; Translational Research, Biomedical |
| Chemical Substances | Inflammation Mediators |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-09 |
| Publishing country | Germany |
| Document type | Journal Article ; Review |
| ZDB-ID | 2543451-2 |
| ISSN | 1674-8018 ; 1674-8018 |
| ISSN (online) | 1674-8018 |
| ISSN | 1674-8018 |
| DOI | 10.1007/s13238-020-00738-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.